



PRIOR AUTHORIZATION POLICY

POLICY: Inflammatory Conditions – Simponi Subcutaneous Prior Authorization Policy

- Simponi® (golimumab subcutaneous injection – Janssen)

REVIEW DATE: 05/10/2023

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Simponi subcutaneous injection, a tumor necrosis factor inhibitor (TNFi), is approved for the following uses:¹

- **Ankylosing spondylitis**, in adults with active disease either alone or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs).
- **Psoriatic arthritis**, in adults with active disease either alone or in combination with methotrexate or other non-biologic DMARDs.
- **Rheumatoid arthritis**, in adults with moderate to severe active disease in combination with methotrexate.
- **Ulcerative colitis**, for inducing and maintaining clinical response, improving endoscopic appearance of the mucosa during induction, inducing clinical remission, and achieving and sustaining clinical remission in induction responders in adults with moderate to severe disease who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.

Guidelines

TNFis are featured prominently in guidelines for treatment of inflammatory conditions.

- **Psoriatic Arthritis:** Guidelines from American College of Rheumatology (ACR) [2019] recommend TNFis over other biologics for use in treatment-naïve patients and in those who were previously treated with an oral therapy.³
- **Rheumatoid Arthritis:** Guidelines from ACR (2015) have TNFis and non-TNF biologics, administered with or without methotrexate, equally positioned as a recommended therapy following a trial of a conventional synthetic DMARD (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine).⁴
- **Spondyloarthritis:** Guidelines for ankylosing spondylitis and non-radiographic axial spondylitis are published by the ACR/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (2019).² TNFis are recommended as the initial biologic. In those who are secondary non-responders to a TNFi, a second TNFi is recommended over switching out of the class.
- **Ulcerative Colitis:** Updated American College of Gastroenterology guidelines for ulcerative colitis (2019) note that the following agents can be used for induction of remission in moderately to severely active disease: budesonide tablets; oral or intravenous systemic corticosteroids, Entyvio® (vedolizumab intravenous infusion), Xeljanz®/XR (tofacitinib tablets/extended-release tablets), or TNFis (adalimumab, Simponi subcutaneous, infliximab).⁵ In addition to the approved indication, clinical guidelines for the management of pouchitis, published in 2009, indicate that first-line therapy for pouchitis is antibiotic therapy (e.g. metronidazole, ciprofloxacin).⁸ Other treatment options include maintenance probiotics, oral or topical budesonide, anti-inflammatory drugs (e.g., mesalamine), or immunosuppressive drugs (e.g., infliximab).

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Simponi Subcutaneous. All approvals are provided for the duration listed below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Simponi Subcutaneous as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Simponi Subcutaneous to be prescribed by or in consultation with a physician who specializes in the condition being treated.

- **Simponi® (golimumab subcutaneous injection – Janssen) is(are) covered as medically necessary when the following criteria is(are) met for fda-approved indication(s) or other uses with supportive evidence (if applicable):**

FDA-Approved Indications

- 1. Ankylosing Spondylitis.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):
 - A) Initial Therapy. Approve for 6 months if prescribed by or in consultation with a rheumatologist.
 - B) Patient is Currently Receiving Simponi (Subcutaneous or Aria). Approve for 1 year if the patient meets BOTH of the following criteria (i and ii):
 - i. Patient has been established on therapy for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).
 - ii. Patient meets at least one of the following criteria (a or b):
 - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating Simponi);
OR
Note: Examples of objective measures include Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S), and/or serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate).
 - b) Compared with baseline (prior to initiating Simponi), patient experienced an improvement in at least one symptom, such as decreased pain or stiffness, or improvement in function or activities of daily living.
- 2. Psoriatic Arthritis.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):
 - A) Initial Therapy. Approve for 6 months if prescribed by or in consultation with a rheumatologist or a dermatologist.
 - B) Patient is Currently Receiving Simponi (Subcutaneous or Aria). Approve for 1 year if the patient meets BOTH of the following criteria (i and ii):
 - i. Patient has been established on therapy for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).
 - ii. Patient meets at least one of the following (a or b):
 - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating Simponi);
OR
Note: Examples of standardized measures of disease activity include Disease Activity Index for Psoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Disease Activity Score (PsA DAS), Grace Index, Leeds Enthesitis Score (LEI), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis score, Leeds Dactylitis Instrument Score, Minimal Disease Activity (MDA), Psoriatic Arthritis Impact of Disease (PsAID-12), and/or serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate).

- b) Compared with baseline (prior to initiating Simponi), patient experienced an improvement in at least one symptom, such as less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths.

3. Rheumatoid Arthritis. Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets BOTH of the following criteria (i and ii):

- i. Patient has tried ONE conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months; AND

Note: Examples of conventional synthetic DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine. An exception to the requirement for a trial of one conventional synthetic DMARD can be made if the patient has already has a 3-month trial with at least one biologic other than the requested drug. A biosimilar of the requested biologic does not count. Refer to Appendix for examples of biologics used for Rheumatoid Arthritis. A patient who has already tried a biologic for rheumatoid arthritis is not required to “step back” and try a conventional synthetic DMARD.

- ii. The medication is prescribed by or in consultation with a rheumatologist.

B) Patient is Currently Receiving Simponi (Subcutaneous or Aria). Approve for 1 year if the patient meets BOTH of the following criteria (i and ii):

- i. Patient has been established on therapy for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).

- ii. Patient meets at least one of the following criteria (a or b):

- a) Patient experienced a beneficial clinical response when assessed by at least one objective measure; OR

Note: Examples of standardized and validated measures of disease activity include Clinical Disease Activity Index (CDAI), Disease Activity Score (DAS) 28 using erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), Patient Activity Scale (PAS)-II, Rapid Assessment of Patient Index Data 3 (RAPID-3), and/or Simplified Disease Activity Index (SDAI).

- b) Patient experienced an improvement in at least one symptom, such as decreased joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths.

4. Ulcerative Colitis. Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following criteria (i, ii, and iii):

- i. Patient is ≥ 18 years of age; AND

- ii. Patient meets ONE of the following criteria (a or b):

- a) Patient has tried one systemic therapy; OR

Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone. A trial of one biologic other than the requested drug also counts as a trial of one systemic agent for ulcerative colitis. A biosimilar of the requested biologic does not count. Refer to Appendix for examples of biologics used for ulcerative colitis.

- b) Patient meets BOTH of the following criteria [(1) and (2)]:
 - (1) Patient has pouchitis; AND
 - (2) Patient has tried therapy with an antibiotic, probiotic, corticosteroid enema, or Rowasa (mesalamine) enema; AND

Note: Examples of antibiotics include metronidazole and ciprofloxacin. Hydrocortisone enema is an example of a corticosteroid enema.
- iii. The medication is prescribed by or in consultation with a gastroenterologist.
- B) Patient is Currently Receiving Simponi (Subcutaneous or Aria). Approve for 1 year if the patient meets BOTH of the following criteria (i and ii):
 - i. Patient has been established on therapy for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).

- ii. Patient meets at least one of the following criteria (a or b):
 - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating Simponi); OR

Note: Examples of assessment for inflammatory response include fecal markers (e.g., fecal calprotectin), serum markers (e.g., C-reactive protein), endoscopic assessment, and/or reduced dose of corticosteroids.

- b) Compared with baseline (prior to initiating Simponi), patient experienced an improvement in at least one symptom, such as decreased pain, fatigue, stool frequency, and/or decreased rectal bleeding.

Other Uses with Supportive Evidence

- 5. Spondyloarthritis, Other Subtypes.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):

Note: This includes undifferentiated arthritis, non-radiographic axial spondyloarthritis, and reactive arthritis (Reiter's disease). For Ankylosing Spondylitis or Psoriatic Arthritis, refer to the respective criteria under FDA-approved indications.

- A) Initial Therapy.** Approve for 6 months if the patient meets BOTH of the following criteria (i and ii):
 - i. Patient meets ONE of the following criteria (a or b):
 - a) Patient meets both of the following criteria [(1) and (2)]:
 - (1) Patient has arthritis primarily in the knees, ankles, elbows, wrists, hands, and/or feet; AND
 - (2) Patient has tried at least ONE conventional synthetic disease-modifying antirheumatic drug (DMARD); OR

Note: Examples of conventional synthetic DMARDs include methotrexate, leflunomide, and sulfasalazine.

- b) Patient has axial spondyloarthritis AND has objective signs of inflammation, defined as at least one of the following criteria [(1) or (2)]:
 - (1) C-reactive protein elevated beyond the upper limit of normal for the reporting laboratory; OR
 - (2) Sacroiliitis reported on magnetic resonance imaging; AND
- ii. The medication is prescribed by or in consultation with a rheumatologist.
- B) Patient is Currently Receiving Simponi (Subcutaneous or Aria).** Approve for 1 year if the patient meets BOTH of the following criteria (i and ii):
 - i. Patient has been established on therapy for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).
 - ii. Patient meets at least one of the following criteria (a or b):
 - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating Simponi); OR
Note: Examples of objective measures include Ankylosing Spondylitis Disease Activity Score (ASDAS) and/or serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate).
 - b) Compared with baseline (prior to initiating Simponi), patient experienced an improvement in at least one symptom, such as decreased pain or stiffness, or improvement in function or activities of daily living.

CONDITIONS NOT COVERED

- **Simponi® (golimumab subcutaneous injection – Janssen)** is(are) considered experimental, investigational or unproven for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

1. Concurrent Use with a Biologic or with a Targeted Synthetic Disease-Modifying Antirheumatic Drug (DMARD). Simponi Subcutaneous should not be administered in combination with another biologic or with a targeted synthetic DMARD used for an inflammatory condition (see Appendix for examples). Combination therapy is generally not recommended due to a potentially higher rate of adverse events with combinations and lack of data supportive of additional efficacy.

Note: This does not exclude the use of conventional synthetic DMARDs (e.g., methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine) in combination with Simponi Subcutaneous.

2. Plaque Psoriasis without Psoriatic Arthritis. Simponi Subcutaneous is indicated in patients with psoriatic arthritis, but it has not been evaluated and it

is not indicated in patients with plaque psoriasis without psoriatic arthritis. Prospective, controlled trials are needed to determine safety and efficacy in plaque psoriasis. Other TNFis (e.g., etanercept, adalimumab, and infliximab products, Cimzia® [certolizumab pegol subcutaneous injection]) are indicated for the treatment of plaque psoriasis.

REFERENCES

1. Simponi® subcutaneous injection [prescribing information]. Horsham, PA: Janssen; September 2019.
2. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol.* 2019;71(10):1599-1613.
3. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. *Arthritis Care Res (Hoboken).* 2019;71(1):2-29.
4. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol.* 2016;68(1):1-26.
5. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol.* 2019;114(3):384-413.
6. Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Ann Rheum Dis.* 2013;72 Suppl 2:ii2-34.
7. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. *Arthritis Rheum.* 2009;60:976-986.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	05/11/2022
Annual Revision	No criteria changes.	05/10/2023

APPENDIX

	Mechanism of Action	Examples of Inflammatory Indications*
Biologics		
Adalimumab SC Products (Humira®, biosimilars)	Inhibition of TNF	AS, CD, JIA, PsO, PsA, RA, UC
Cimzia® (certolizumab pegol SC injection)	Inhibition of TNF	AS, CD, nr-axSpA, PsO, PsA, RA
Etanercept SC Products (Enbrel®, biosimilars)	Inhibition of TNF	AS, JIA, PsO, PsA
Infliximab IV Products (Remicade®, biosimilars)	Inhibition of TNF	AS, CD, PsO, PsA, RA, UC
Simponi®, Simponi® Aria™ (golimumab SC injection, golimumab IV infusion)	Inhibition of TNF	SC formulation: AS, PsA, RA, UC
		IV formulation: AS, PJIA, PsA, RA
Actemra® (tocilizumab IV infusion, tocilizumab SC injection)	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA
		IV formulation: PJIA, RA, SJIA
Kevzara® (sarilumab SC injection)	Inhibition of IL-6	RA
Orencia® (abatacept IV infusion, abatacept SC injection)	T-cell costimulation modulator	SC formulation: JIA, PsA, RA
		IV formulation: JIA, PsA, RA
Rituximab IV Products (Rituxan®, biosimilars)	CD20-directed cytolytic antibody	RA
Kineret® (anakinra SC injection)	Inhibition of IL-1	JIA [^] , RA
Stelara® (ustekinumab SC injection, ustekinumab IV infusion)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC
		IV formulation: CD, UC
Siliq™ (brodalumab SC injection)	Inhibition of IL-17	PsO
Cosentyx® (secukinumab SC injection)	Inhibition of IL-17A	AS, ERA, nr-axSpA, PsO, PsA
Taltz® (ixekizumab SC injection)	Inhibition of IL-17A	AS, nr-axSpA, PsO, PsA
Ilumya™ (tildrakizumab-asmn SC injection)	Inhibition of IL-23	PsO
Skyrizi® (risankizumab-rzaa SC injection)	Inhibition of IL-23	PsA, PsO
Tremfya™ (guselkumab SC injection)	Inhibition of IL-23	PsO
Entyvio™ (vedolizumab IV infusion)	Integrin receptor antagonist	CD, UC
Oral Therapies/Targeted Synthetic DMARDs		
Otezla® (apremilast tablets)	Inhibition of PDE4	PsO, PsA
Cibinqo™ (abrocitinib tablets)	Inhibition of JAK pathways	AD
Olumiant® (baricitinib tablets)	Inhibition of JAK pathways	RA
Rinvoq® (upadacitinib extended-release tablets)	Inhibition of JAK pathways	AD, RA, PsA, UC
Xeljanz® (tofacitinib tablets)	Inhibition of JAK pathways	RA, PJIA, PsA, UC
Xeljanz® XR (tofacitinib extended-release tablets)	Inhibition of JAK pathways	RA, PsA, UC

* Not an all-inclusive list of indication (e.g., oncology indications and rare inflammatory conditions are not listed). Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn’s disease; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; IV – Intravenous, PJIA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJIA – Systemic juvenile idiopathic

arthritis; ^ Off-label use of Kineret in JIA supported in guidelines; ERA – Enthesitis-related arthritis; DMARDs – Disease-modifying antirheumatic drug; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AD – Atopic dermatitis.

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna